U.S. Stem Cell Reports Debt Restructuring Agreement

U.S. Stem Cell (OTCQB:USRM) submitted a Form 8-K to the US Securities and Exchange Commission (SEC), reporting a debt restructuring agreement.
As quoted in the press release:

The Hunton agreement is part of U.S. Stem Cell, Inc.’s continued effort to clean up the balance sheet and lower the company’s debt. This agreement is estimated to provide a debt relief of approximately $393,180. A copy of the SEC Form 8-K filing is available at: https://www.sec.gov/Archives/edgar/data/1388319/000118518517001988/usstemcell8k091117.htm
“Treating patients, generating revenue and restructuring debt has always been a top priority at US Stem Cell Inc,” said the company’s President & CEO, Mike Tomas. “Hunton & Williams has been an extraordinary legal partner of the company and we are very grateful for their continued support. Negotiating the Hunton debt allows the company to freeze the interest payments on two notes from 2009 and begin to work towards paying off this long-standing debt.”

Click here to read the full press release.

Source: www.accesswire.com